3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Ovarian Neoplasms
2
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
2
fludarabine
2
SS1(dsFv)PE38
2
Platinum
2
Hyperthermic Intraperitoneal Chemotherapy
2
Cyclophosphamide
2
Cisplatin
2
1,2-diaminocyclohexaneplatinum II citrate
2
sodium thiosulfate
1
enzalutamide
1
entinostat
1
X-Rays
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Specimen Handling
1
Referral and Consultation
1
Polymerase Chain Reaction
1
Paclitaxel
1
Nivolumab
1
Microarray Analysis
1
Megestrol Acetate
1
Magnetic Resonance Spectroscopy
1
Levoleucovorin
1
Leucovorin
1
Ipilimumab
1
Interleukin-2
1
In Situ Hybridization, Fluorescence
1
Immunoenzyme Techniques
1
Gene Expression Profiling
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
Blood Component Removal
×
Gynecologic
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled